232 related articles for article (PubMed ID: 34871373)
61. CD19 targeted CAR-T therapy versus chemotherapy in re-induction treatment of refractory/relapsed acute lymphoblastic leukemia: results of a case-controlled study.
Wei G; Hu Y; Pu C; Yu J; Luo Y; Shi J; Cui Q; Wu W; Wang J; Xiao L; Wu Z; Huang H
Ann Hematol; 2018 May; 97(5):781-789. PubMed ID: 29417201
[TBL] [Abstract][Full Text] [Related]
62. Kinetics of immune reconstitution after anti-CD19 chimeric antigen receptor T cell therapy in relapsed or refractory acute lymphoblastic leukemia patients.
Wang Y; Li H; Song X; Qi K; Cheng H; Cao J; Shi M; Yan Z; Jing G; Pan B; Sang W; Wang X; Zhao K; Chen C; Chen W; Zheng J; Li Z; Xu K
Int J Lab Hematol; 2021 Apr; 43(2):250-258. PubMed ID: 33112046
[TBL] [Abstract][Full Text] [Related]
63. CD19/22 CAR T cells in children and young adults with B-ALL: phase 1 results and development of a novel bicistronic CAR.
Shalabi H; Qin H; Su A; Yates B; Wolters PL; Steinberg SM; Ligon JA; Silbert S; DéDé K; Benzaoui M; Goldberg S; Achar S; Schneider D; Shahani SA; Little L; Foley T; Molina JC; Panch S; Mackall CL; Lee DW; Chien CD; Pouzolles M; Ahlman M; Yuan CM; Wang HW; Wang Y; Inglefield J; Toledo-Tamula MA; Martin S; Highfill SL; Altan-Bonnet G; Stroncek D; Fry TJ; Taylor N; Shah NN
Blood; 2022 Aug; 140(5):451-463. PubMed ID: 35605184
[TBL] [Abstract][Full Text] [Related]
64. T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial.
Lee DW; Kochenderfer JN; Stetler-Stevenson M; Cui YK; Delbrook C; Feldman SA; Fry TJ; Orentas R; Sabatino M; Shah NN; Steinberg SM; Stroncek D; Tschernia N; Yuan C; Zhang H; Zhang L; Rosenberg SA; Wayne AS; Mackall CL
Lancet; 2015 Feb; 385(9967):517-528. PubMed ID: 25319501
[TBL] [Abstract][Full Text] [Related]
65. Factors associated with durable EFS in adult B-cell ALL patients achieving MRD-negative CR after CD19 CAR T-cell therapy.
Hay KA; Gauthier J; Hirayama AV; Voutsinas JM; Wu Q; Li D; Gooley TA; Cherian S; Chen X; Pender BS; Hawkins RM; Vakil A; Steinmetz RN; Schoch G; Chapuis AG; Till BG; Kiem HP; Ramos JD; Shadman M; Cassaday RD; Acharya UH; Riddell SR; Maloney DG; Turtle CJ
Blood; 2019 Apr; 133(15):1652-1663. PubMed ID: 30728140
[TBL] [Abstract][Full Text] [Related]
66. Long-term follow-up of CD19 chimeric antigen receptor T-cell therapy for relapsed/refractory acute lymphoblastic leukemia after allogeneic hematopoietic stem cell transplantation.
Chen YH; Zhang X; Cheng YF; Chen H; Mo XD; Yan CH; Chen Y; Han W; Sun YQ; Wang Y; Zhang XH; Xu LP; Liu KY; Yang J; Zhang J; Zhang GL; Shi Y; Su YC; Li WQ; Xu L; Song D; Zhang M; Lu P; Huang XJ
Cytotherapy; 2020 Dec; 22(12):755-761. PubMed ID: 32861622
[TBL] [Abstract][Full Text] [Related]
67. [CAR-T therapy for pediatric acute lymphoblastic leukemia].
Sakaguchi H
Rinsho Ketsueki; 2023; 64(11):1440-1446. PubMed ID: 38072432
[TBL] [Abstract][Full Text] [Related]
68. Analysis benefits of a second Allo-HSCT after CAR-T cell therapy in patients with relapsed/refractory B-cell acute lymphoblastic leukemia who relapsed after transplant.
Cao XY; Zhang JP; Zhao YL; Xiong M; Zhou JR; Lu Y; Sun RJ; Wei ZJ; Liu DY; Zhang X; Yang JF; Lu P
Front Immunol; 2023; 14():1191382. PubMed ID: 37469510
[TBL] [Abstract][Full Text] [Related]
69. Tisagenlecleucel therapy for relapsed or refractory B-cell acute lymphoblastic leukaemia in infants and children younger than 3 years of age at screening: an international, multicentre, retrospective cohort study.
Ghorashian S; Jacoby E; De Moerloose B; Rives S; Bonney D; Shenton G; Bader P; Bodmer N; Quintana AM; Herrero B; Algeri M; Locatelli F; Vettenranta K; Gonzalez B; Attarbaschi A; Harris S; Bourquin JP; Baruchel A
Lancet Haematol; 2022 Oct; 9(10):e766-e775. PubMed ID: 36084658
[TBL] [Abstract][Full Text] [Related]
70. Chimeric antigen receptor T cells for acute lymphoblastic leukemia.
Frey NV
Am J Hematol; 2019 May; 94(S1):S24-S27. PubMed ID: 30784101
[TBL] [Abstract][Full Text] [Related]
71. A report on Lineage switch at relapse of CD19 CAR-T therapy for Philadelphia chromosome-positive B-precursor acute lymphoblastic leukemia.
Li LZ; Sun Q; Fang Y; Yang LJ; Xu ZY; Hu JH; Cao L; Huang JY; Hong M; Li JY; Qian SX
Chin Med J (Engl); 2020 Aug; 133(16):2001-2003. PubMed ID: 32826471
[No Abstract] [Full Text] [Related]
72. [Safety and efficacy of humanized CD19-targeted CAR-T cells in patients with relapsed/refractory acute B cell lymphoblastic leukemia].
Song FM; Hu YX; Zhang MM; Wu WW; Xu HJ; Zhang HS; Huang H; Wei GQ
Zhonghua Xue Ye Xue Za Zhi; 2022 Aug; 43(8):651-656. PubMed ID: 36709149
[No Abstract] [Full Text] [Related]
73. The European Medicines Agency Review of Kymriah (Tisagenlecleucel) for the Treatment of Acute Lymphoblastic Leukemia and Diffuse Large B-Cell Lymphoma.
Ali S; Kjeken R; Niederlaender C; Markey G; Saunders TS; Opsata M; Moltu K; Bremnes B; Grønevik E; Muusse M; Håkonsen GD; Skibeli V; Kalland ME; Wang I; Buajordet I; Urbaniak A; Johnston J; Rantell K; Kerwash E; Schuessler-Lenz M; Salmonson T; Bergh J; Gisselbrecht C; Tzogani K; Papadouli I; Pignatti F
Oncologist; 2020 Feb; 25(2):e321-e327. PubMed ID: 32043764
[TBL] [Abstract][Full Text] [Related]
74. Efficacy and safety of tisagenlecleucel in Japanese pediatric and young adult patients with relapsed/refractory B cell acute lymphoblastic leukemia.
Hiramatsu H; Adachi S; Umeda K; Kato I; Eldjerou L; Agostinho AC; Natsume K; Tokushige K; Watanabe Y; Grupp SA
Int J Hematol; 2020 Feb; 111(2):303-310. PubMed ID: 31709501
[TBL] [Abstract][Full Text] [Related]
75. Comparable outcomes in patients with B-cell acute lymphoblastic leukemia receiving haploidentical hematopoietic stem cell transplantation: Pretransplant minimal residual disease-negative complete remission following chimeric antigen receptor T-cell therapy versus chemotherapy.
Yang TT; Meng Y; Kong DL; Wei GQ; Zhang MM; Wu WJ; Shi JM; Luo Y; Zhao YM; Yu J; Jing RR; Zhao MY; Zhao HL; Huang H; Hu YX
Front Immunol; 2022; 13():934442. PubMed ID: 36110859
[TBL] [Abstract][Full Text] [Related]
76. Humanized CD19-directed CAR-T Cell Therapy in Pediatric Relapsed/Refractory Acute Lymphoblastic Leukemia With CNSL or Neurological Comorbidity.
Zhang N; Shao J; Li H; Zhu J; Xia M; Chen K; Jiang H
J Immunother; 2022 Nov-Dec 01; 45(9):396-406. PubMed ID: 36018262
[TBL] [Abstract][Full Text] [Related]
77. Fludarabine exposure predicts outcome after CD19 CAR T-cell therapy in children and young adults with acute leukemia.
Dekker L; Calkoen FG; Jiang Y; Blok H; Veldkamp SR; De Koning C; Spoon M; Admiraal R; Hoogerbrugge P; Vormoor B; Vormoor HJ; Visscher H; Bierings M; Van Der Vlugt M; Van Tinteren H; Nijstad AL; Huitema ADR; Van Der Elst KCM; Pieters R; Lindemans CA; Nierkens S
Blood Adv; 2022 Apr; 6(7):1969-1976. PubMed ID: 35134115
[TBL] [Abstract][Full Text] [Related]
78. Higher doses of tisagenlecleucel are associated with improved outcomes: a report from the pediatric real-world CAR consortium.
Stefanski HE; Eaton A; Baggott C; Rossoff J; Verneris MR; Prabhu S; Pacenta HL; Phillips CL; Talano JA; Moskop A; Margossian SP; Myers GD; Karras NA; Brown PA; Qayed M; Hermiston M; Satwani P; Krupski MC; Keating AK; Wilcox R; Rabik CA; Fabrizio VA; Chinnabhandar V; Goksenin AY; Curran KJ; Mackall CL; Laetsch TW; Schultz LM
Blood Adv; 2023 Feb; 7(4):541-548. PubMed ID: 35938863
[TBL] [Abstract][Full Text] [Related]
79. Locally produced CD19 CAR T cells leading to clinical remissions in medullary and extramedullary relapsed acute lymphoblastic leukemia.
Jacoby E; Bielorai B; Avigdor A; Itzhaki O; Hutt D; Nussboim V; Meir A; Kubi A; Levy M; Zikich D; Zeltzer LA; Brezinger K; Schachter J; Nagler A; Besser MJ; Toren A
Am J Hematol; 2018 Dec; 93(12):1485-1492. PubMed ID: 30187944
[TBL] [Abstract][Full Text] [Related]
80. Efficiency of CD19 chimeric antigen receptor-modified T cells for treatment of B cell malignancies in phase I clinical trials: a meta-analysis.
Zhang T; Cao L; Xie J; Shi N; Zhang Z; Luo Z; Yue D; Zhang Z; Wang L; Han W; Xu Z; Chen H; Zhang Y
Oncotarget; 2015 Oct; 6(32):33961-71. PubMed ID: 26376680
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
